| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/13/2000 | WO2000020588A2 Bone marrow-derived serum proteins |
| 04/13/2000 | WO2000020587A2 Cancer associated antigens and uses therefor |
| 04/13/2000 | WO2000020586A2 Renal cancer associated antigens and uses therefor |
| 04/13/2000 | WO2000020584A2 Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6 |
| 04/13/2000 | WO2000020583A1 Ribonucleoprotein homolog zrnp1, having also homology to the gnrh receptor |
| 04/13/2000 | WO2000020582A2 Gene replacement therapy for muscular dystrophy |
| 04/13/2000 | WO2000020581A1 Mage-a3 peptides presented by hla class ii molecules |
| 04/13/2000 | WO2000020579A1 Spliced form of erbb-2/neu oncogene |
| 04/13/2000 | WO2000020578A1 A method of modulating cell survival and reagents useful for same |
| 04/13/2000 | WO2000020577A1 Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth |
| 04/13/2000 | WO2000020576A2 Methods and compositions for inducing differentiation and apotosis in cells that overexpess the notch protein |
| 04/13/2000 | WO2000020572A2 Tissue binding peptides, identification, production and utilization thereof |
| 04/13/2000 | WO2000020570A1 Enzyme producing plasma protein fragment having effect of inhibiting cancer metastasis and plasma protein fragment fragmented by the enzyme |
| 04/13/2000 | WO2000020560A1 Engraftable neural progenitor and stem cells for brain tumor therapy |
| 04/13/2000 | WO2000020559A1 Method for the treatment of chemonucleolysis |
| 04/13/2000 | WO2000020457A1 Peptides related to an igf-ii-r epitope, polynucleotides encoding the peptides, and their use in immunomodulation |
| 04/13/2000 | WO2000020456A1 Novel g protein-coupled receptor protein and dna thereof |
| 04/13/2000 | WO2000020453A1 Chemical structure with affinity for a phospholipid, and marker compound, diagnosis kit, and medicine comprising said structure |
| 04/13/2000 | WO2000020450A2 Calcium channel alpha-2/delta gene |
| 04/13/2000 | WO2000020449A2 MODIFIED TGF-β SUPERFAMILY PROTEINS |
| 04/13/2000 | WO2000020448A2 Nlk1 -interacting proteins |
| 04/13/2000 | WO2000020447A2 Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses |
| 04/13/2000 | WO2000020446A2 Bax-mediated apoptosis modulating reagents and methods |
| 04/13/2000 | WO2000020445A2 Tumor antigens and ctl clones isolated by a novel procedure |
| 04/13/2000 | WO2000020444A1 Novel peptides |
| 04/13/2000 | WO2000020443A1 Novel peptides |
| 04/13/2000 | WO2000020442A1 Tumor-specific antigen peptides |
| 04/13/2000 | WO2000020440A1 Caspases and apoptosis |
| 04/13/2000 | WO2000020434A1 Cadherin-like asymmetry protein-1, and methods for its use |
| 04/13/2000 | WO2000020432A1 Antisense modulation of bcl-x expression |
| 04/13/2000 | WO2000020392A1 Aryl-substituted propanolamine derivatives, methods for their production, medicaments containing said compounds and their use |
| 04/13/2000 | WO2000020041A2 Removal of preexisting antibodies to enhance the effectiveness of a therapeutic viral immunogenic agent |
| 04/13/2000 | WO2000020038A1 Method of treating prostate cancer with an adenovirus vector |
| 04/13/2000 | WO2000020037A1 A novel component in the hedgehog signalling pathway |
| 04/13/2000 | WO2000020034A1 Agents for retarding change of hormone-dependent cancer into hormone-independent cancer |
| 04/13/2000 | WO2000020031A1 Methods for identification, diagnosis, and treatment of breast cancer |
| 04/13/2000 | WO2000020026A2 Compositions and methods for inhibiting angiogenesis |
| 04/13/2000 | WO2000020025A2 Akt compositions for enhancing survival of cells |
| 04/13/2000 | WO2000020024A2 Methods for the treatment of non-thyroid disorders |
| 04/13/2000 | WO2000020023A2 Null igf for the treatment of cancer |
| 04/13/2000 | WO2000020022A1 Methods for the treatment of cancer using cytokines in combination with low level doses of chemotherapy and/or radiotherapy |
| 04/13/2000 | WO2000020021A1 Repair of larynx, trachea, and other fibrocartilaginous tissues |
| 04/13/2000 | WO2000020020A2 Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease |
| 04/13/2000 | WO2000020019A2 A composition for the prevention and/or treatment of atherosclerosis |
| 04/13/2000 | WO2000020018A1 Kappa-a conopeptides and uses therefor |
| 04/13/2000 | WO2000020014A1 Plant extracts for the treatment of increased bone resorption |
| 04/13/2000 | WO2000020011A1 Isolated dna encoding human h3 histamine receptor |
| 04/13/2000 | WO2000020007A1 Method and compositions for increasing bone mass |
| 04/13/2000 | WO2000019988A1 NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF |
| 04/13/2000 | WO2000019978A2 Compositions and methods for enhancing receptor-mediated cellular internalization |
| 04/13/2000 | WO2000019974A1 Method for prevention and/or cosmetic treatment of skin striae and use in dermatology |
| 04/13/2000 | WO2000019883A2 Compositions and methods of disease diagnosis and therapy |
| 04/13/2000 | WO2000019824A1 Novel treatment for stroke management |
| 04/13/2000 | WO2000019823A1 Methods of screening for apoptosis-controlling agents for bone anabolic therapies and uses thereof |
| 04/13/2000 | WO2000003015A3 Human transport protein homologs |
| 04/13/2000 | WO2000002916A3 PEPTIDE COMPOSITIONS MIMICKING TGF-β ACTIVITY |
| 04/13/2000 | WO2000001831A3 Proteases fused with variants of streptomyces subtilisin inhibitor |
| 04/13/2000 | WO2000001813A3 Peptide inhibitors of androgen-independent activation of androgen receptor |
| 04/13/2000 | WO2000001415A3 Use of inhibitors of protein kinase c epsilon to treat pain |
| 04/13/2000 | WO2000000608A3 Immune system molecules |
| 04/13/2000 | WO2000000603A3 Modularly constructed rna molecules having two sequence region types |
| 04/13/2000 | WO2000000588A3 Porcine spinal cord cells and their use in spinal cord repair |
| 04/13/2000 | WO2000000509A3 Peptides for inhibiting hpv e7 proteins |
| 04/13/2000 | WO1999065924A3 Preparation and use of superior vaccines |
| 04/13/2000 | WO1999064576A3 Human genes differentially expressed in colon cancer |
| 04/13/2000 | WO1999063094A3 Nucleotide and protein sequences of gpr1 and methods based thereon |
| 04/13/2000 | WO1999061072A3 Methods of inhibiting clot formation |
| 04/13/2000 | WO1999055720A9 Targeted gene delivery to cells by filamentous bacteriophage |
| 04/13/2000 | CA2657302A1 Modified tgf-.beta. superfamily proteins |
| 04/13/2000 | CA2347120A1 Nlk1 -interacting proteins |
| 04/13/2000 | CA2346765A1 Compositions and methods of disease diagnosis and therapy |
| 04/13/2000 | CA2346695A1 Methods of screening for apoptosis-controlling agents for bone anabolic therapies and uses thereof |
| 04/13/2000 | CA2346665A1 Novel treatment for stroke management |
| 04/13/2000 | CA2346496A1 Novel th2-specific molecules and uses thereof |
| 04/13/2000 | CA2346459A1 In vitro and in vivo models for screening compounds to prevent glucocorticoid-induced bone destruction |
| 04/13/2000 | CA2346456A1 Method and compositions for increasing bone mass |
| 04/13/2000 | CA2346375A1 Method for the treatment of chemonucleolysis |
| 04/13/2000 | CA2346217A1 Extracellular novel rage binding protein (en-rage) and uses thereof |
| 04/13/2000 | CA2346070A1 Bax-mediated apoptosis modulating reagents and methods |
| 04/13/2000 | CA2346048A1 Methods for identification, diagnosis, and treatment of breast cancer |
| 04/13/2000 | CA2345881A1 Bone marrow-derived serum proteins |
| 04/13/2000 | CA2345642A1 Methods for the treatment of non-thyroid disorders |
| 04/13/2000 | CA2345477A1 Peptides related to an igf-ii-r epitope, polynucleotides encoding the peptides, and their use in immunomodulation |
| 04/13/2000 | CA2345408A1 Removal of preexisting antibodies to enhance the effectiveness of a therapeutic viral immunogenic agent |
| 04/13/2000 | CA2345377A1 Novel secreted proteins and polynucleotides encoding them |
| 04/13/2000 | CA2345375A1 Chemical structure with affinity for a phospholipid, and marker compound, diagnosis kit, and medicine comprising said structure |
| 04/13/2000 | CA2345214A1 Tissue binding peptides, identification, production and utilization thereof |
| 04/13/2000 | CA2345213A1 Agent that retards transformation of hormone-dependent cancer to non-hormone-dependent cancer |
| 04/13/2000 | CA2345209A1 Antisense modulation of integrin .alpha.4 expression |
| 04/13/2000 | CA2345045A1 G-protein coupled receptor proteins |
| 04/13/2000 | CA2345023A1 Peptides useful for reducing symptoms of toxic shock syndrome and septic shock |
| 04/13/2000 | CA2344995A1 Cancer associated antigens and uses therefor |
| 04/13/2000 | CA2344973A1 Oxidoreductase molecules |
| 04/13/2000 | CA2344765A1 Novel peptides |
| 04/13/2000 | CA2344616A1 Antisense oligonucleotide modulation of tumor necrosis factor-.alpha. (tnf-.alpha.) expression |
| 04/13/2000 | CA2344613A1 Compositions and methods for inhibiting angiogenesis |
| 04/13/2000 | CA2344563A1 Methods and compositions for the diagnosis and therapy of prostate cancer |
| 04/13/2000 | CA2344552A1 Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6 |
| 04/13/2000 | CA2344551A1 P-conotoxin peptide |
| 04/13/2000 | CA2344459A1 Novel g protein-coupled receptor protein and dna thereof |